
WAT gains FDA clearance for two blood cancer diagnostic tests, advancing standardized testing and expanding its clinical diagnostics portfolio.
Waters Corporation is a publicly traded Analytical Laboratory instrument and software company headquartered in Milford, Massachusetts.
| Revenue (TTM) | $5.61B |
| Gross Profit (TTM) | $3.11B |
| EBITDA | $1.76B |
| Operating Margin | 16.00% |
| Return on Equity | 1.12% |
| Return on Assets | 3.87% |
| Revenue/Share (TTM) | $66.00 |
| Book Value | $155.60 |
| Price-to-Book | 5.92 |
| Price-to-Sales (TTM) | 16.12 |
| EV/Revenue | 8.94 |
| EV/EBITDA | 43.54 |
| Quarterly Earnings Growth (YoY) | -67.00% |
| Quarterly Revenue Growth (YoY) | 120.90% |
| Shares Outstanding | $98.29M |
| Float | $98.10M |
| % Insiders | 0.58% |
| % Institutions | 103.74% |
Volatility is currently expanding

WAT gains FDA clearance for two blood cancer diagnostic tests, advancing standardized testing and expanding its clinical diagnostics portfolio.

BD OneFlow™ LST and BD OneFlow™ B-CLPD T1 Tests now FDA 510(k)-cleared in U.S. for identifying B-cell non-Hodgkin lymphoma (NHL) Delivers 96.3% sensitivity and 98.2% specificity1 in identifying chronic lymphocytic leukemia (CLL), one of the most common types of NHL All-in-one solution reduces 95% of manual steps,2 delivering workflow efficiency, fast turnaround times, and a reduction in errors MILFORD, Mass., Nov. 10, 2026 /PRNewswire/ -- Waters Corporation (NYSE: WAT) today announced that the BD OneFlow LST Test and BD OneFlow B-CLPD T1 Test have received U.S. Food and Drug Administration (FDA) 510(k) clearance.

WAT expands its proteomics footprint with the MOBILion acquisition, boosting mass spectrometry capabilities, AI-driven research and clinical testing prospects.

The Madison Mid Cap Fund (Class I) returned -2.09% in the third quarter, compared to the Russell Midcap Index return of -3.00%. The top five contributors for the quarter were Gartner, Medpace Holdings, Ross Stores, Revvity, and Waters Corporation. The bottom five detractors for the quarter were MKS, Floor & Decor Holdings, Carlisle Companies, Moelis and Co., and Glacier Bancorp.

Jim Cramer just declared the companies that supply drug labs and research instruments the true heirs to the data center trade, and three stocks are already beating the NASDAQ-100 by a wide margin this year.

Waters NYSE: WAT reported third-quarter 2026 revenue of $1.767 billion and adjusted earnings per share of $4.10, as the company cited double-digit organic growth, improving performance in acquired businesses and cost actions that supported profitability.

WAT beats Q3 2026 earnings and revenue estimates, fueled by acquisitions and strong organic growth and raises its full-year revenue and earnings outlook.

Waters Corporation (WAT) Q3 2026 Earnings Call Transcript

The headline numbers for Waters (WAT) give insight into how the company performed in the quarter ended September 2026, but it may be worthwhile to compare some of its key metrics to Wall Street estimates and the year-ago actuals.

Waters (WAT) came out with quarterly earnings of $4.1 per share, beating the Zacks Consensus Estimate of $3.99 per share. This compares to earnings of $3.4 per share a year ago.
Tiblio connects your broker and runs your put-and-call-writing strategy for you — on WAT and any ticker you trade — then tracks every position and per-strategy win rate.